Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 2412345...1020...Last »

Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib

Cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival at the planned second interim analysis for the population of second-line and third-line patients enrolled in the CELESTIAL study.

Read More »

Eiger to abandon blood pressure drug

Eiger BioPharmaceuticals Inc. will stop development of a drug to treat pulmonary arterial hypertension after it failed in a mid-stage study.

Read More »

Odonate Therapeutics Announces Initiation of Phase 3 Study for Metastatic Breast Cancer

Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.

Read More »

Celgene’s Follicular Lymphoma Regimen Fails Phase III

Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.

Read More »

Shire’s Hunter Syndrome Treatment Fails Study Goals

Shire’s experimental treatment SHP609 to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial.

Read More »

Allergan, Richter’s bipolar depression drug succeeds in key trial

Allergan and Gedeon Richter’s drug cariprazine to treat severe bipolar depression in adults met the main goal of a late-stage study.

Read More »

Keytruda Fails Phase III Stomach Cancer Study

Merck & Co.’s Keytruda came up short in a pivotal study as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Read More »

Bumper crop of new drugs fails to lift big pharma R&D returns

2017 has shaped up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.

Read More »

Genentech’s Hemlibra Data Wows at ASH

At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.

Read More »

Breast cancer drug superior to chemo in study

Pfizer’s talazoparib for advanced breast cancer was demonstrated to be superior to chemotherapy in a late-stage study.

Read More »

Roche study: Cancer ‘Velcro’ halts T-cell attack

Roche scientists may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.

Read More »

Sage’s depression drug succeeds in study

Sage Therapeutics Inc.’s drug to treat patients with moderate to severe depression met the main goal in a mid-stage study.

Read More »

Sanofi’s Toujeo met main objective in study

Sanofi’s Toujeo met the primary study objective in the first large head-to-head clinical trial, called BRIGHT study, comparing Toujeo with insulin degludec.

Read More »

Sanofi ends development of C. difficile vaccine

Sanofi SA ended development of an experimental vaccine for Clostridium difficile infection.

Read More »

Bristol-Myers’ Lung Cancer Opdivo Trial Stopped Early for Superior Overall Survival

Bristol-Myers Squibb announced that the company’s Phase III trial pitting Opdivo against chemotherapy drug docetaxel in treating certain lung cancer patients was stopped early after meeting key endpoints.

Read More »

Aimovig Halves Length of Migraine Attacks in Study

Amgen unveiled results from a late-stage study that shows the company’s Phase III drug Aimovig reduced monthly migraine attacks in half.

Read More »

Merck KGaA, Pfizer’s immunotherapy fails in gastric cancer trial

Germany’s Merck KGaA suffered a setback in the development of the company’s key cancer immunotherapy Bavencio, which failed in a trial to prolong lives in gastric cancer patients when compared with standard chemotherapy.

Read More »

Ardelyx to Ditch Phase III Hyperkalemia Drug

Ardelyx decided to shutter development of RDX7675 – an experimental medicine for hyperkalemia – including the onset-of-action trial and Phase III studies.

Read More »

Cytokinetics abandons ALS drug after failed trial, shares tank

Cytokinetics Inc. will stop developing one of its treatments for ALS – which afflicts Stephen Hawking – after the drug failed in a late-stage trial, sending the company’s shares tumbling about 35 percent.

Read More »

Roche stock up $12 billion on cancer, hemophilia trials

Roche shares were lifted by two clinical trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.

Read More »

Page 1 of 2412345...1020...Last »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2017 Focus: Ad Agency Roundtable and more!

Subscribe

Ad Right Bottom

Main Navigation